---
title: "Bank of America Securities raises the target price for SKB BIO to 522 yuan, reiterating a \"Neutral\" rating"
description: "Bank of America Securities raised the target price for SKB BIO from 471.5 yuan to 522 yuan, maintaining a \"Neutral\" rating. This move is based on clinical progress meeting expectations, although short"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262170575.md"
published_at: "2025-10-22T06:21:30.000Z"
---

# Bank of America Securities raises the target price for SKB BIO to 522 yuan, reiterating a "Neutral" rating

> Bank of America Securities raised the target price for SKB BIO from 471.5 yuan to 522 yuan, maintaining a "Neutral" rating. This move is based on clinical progress meeting expectations, although short-term authorization opportunities are limited. The report noted that sac-TMT and A166 performed well in terms of progression-free survival data, and the National Medical Products Administration has approved sac-TMT for second-line EGFR mutation non-small cell lung cancer and A166 for second-line and above HER2-positive breast cancer, thus raising the target price and increasing revenue forecasts for 2025 to 2027 by 1% to 5%

Bank of America Securities published a report, raising the target price for SKB BIO (06990.HK) from HKD 471.5 to HKD 522; reaffirming a "Neutral" rating. This is due to clinical progress meeting expectations, but short-term authorization opportunities are limited.

The firm indicated that the target price was raised to reflect encouraging data showing significant improvements in progression-free survival (PFS) for sac-TMT and A166, as well as the recent approval by the National Medical Products Administration for sac-TMT for second-line EGFR mutation non-small cell lung cancer (NSCLC) and A166 for second-line and above HER2-positive breast cancer (BC). Consequently, revenue forecasts for 2025 to 2027 were increased by 1% to 5%, along with an upward adjustment of long-term forecasts

### Related Stocks

- [06990.HK - SKB BIO-B](https://longbridge.com/en/quote/06990.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Alsobrooks becomes first Senator to endorse Crockett in Texas Senate race | Sen. Angela Alsobrooks (D-Md.) has endorsed Rep. Jasmine Crockett (D-Texas) in the Democratic primary for the Texas Sena | [Link](https://longbridge.com/en/news/276272934.md) |
| Jeffries meets with Maryland Senate president opposed to congressional redistricting | House Minority Leader Hakeem Jeffries met with Maryland Senate President Bill Ferguson to discuss congressional redistri | [Link](https://longbridge.com/en/news/276264174.md) |
| Jesse Jackson funeral: What to know | The Rev. Jesse Jackson will be memorialized in Chicago in the coming weeks following his death at 84. His family celebra | [Link](https://longbridge.com/en/news/276261617.md) |
| Almost 7 in 10 say Epstein files show powerful people rarely held accountable: Poll | A recent Reuters/Ipsos poll reveals that 69% of Americans believe the Jeffrey Epstein files indicate that powerful indiv | [Link](https://longbridge.com/en/news/276244372.md) |
| I'm 72 and started claiming Social Security at 69. Will I get more money if I work part-time? | The Social Security Administration allows beneficiaries to work part-time after starting benefits, potentially increasin | [Link](https://longbridge.com/en/news/276239179.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.